Overview Research Programs Shared Facilities News & Outreach Technology Transfer Employment About PHRI


  World TB Day Symposium: March 24, 2015

KochMarch 24, 2015, was World Tuberculosis Day (TB Day). On March 24, 1882, Dr. Robert Koch announced the discovery of Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB). During this time, TB killed one out of every seven people living in the United States and Europe. Dr. Koch’s discovery was the most important step taken toward the control and elimination of this deadly disease. In 1982, a century after Dr. Koch's announcement, the first World TB Day was sponsored by the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease (IUATLD). The event was intended to educate the public about the devastating health and economic consequences of TB, its effect on developing countries, and its continued tragic impact on global health. Today, World TB Day is commemorated across the globe, but more must be done to raise awareness about the effects of TB. Among infectious diseases, TB remains the second leading killer of adults in the world, with approximately1.5 million TB-related deaths in 2013. Until TB is controlled, World TB Day won’t be a celebration, but it is a valuable opportunity to educate the public about the devastation TB can spread and how it can be stopped. PHRI has a long history of research on the research and clinical aspects of TB. This year, several faculty members from PHRI and other departments at the New Jersey Medical School participated in the World TB Day symposium that was held on March 23 and 24 at the Wadsworth Center of the New York State Department of Health in Albany, New York. Drs. Barry Kreiswirth, Marcela Rodriguez and Maria Gennaro of PHRI gave talks as did Drs. Padmini Salgame and Joel Freundlich of the Department of Medicine.

A history on Tuberculosis research at PHRI can be read in the following PDF document

Follow this link to download a PDF copy of the World TB Day symposium

Paper Highlight

The Path of Anti-Tuberculosis Drugs: From Blood to Lesions to Mycobacterial Cells

For the successful treatment of pulmonary tuberculosis (TB), drugs need to penetrate complex lung lesions and permeate the mycobacterial cell wall in order to reach their cellular targets. However, most currently used anti-tuberculosis drugs were introduced into clinical use without considering the pharmacokinetic and pharmacodynamic (PK/PD) properties that influence drug distribution, and this has contributed to the long duration and limited success of current therapies. Dr. Veronique Dartois, a PHRI faculty member, is an internationally recognized expert in studying the PK/PD of anti-tuberculosis drugs. Dr. Dartois has written a review on this important area of research, entitled “The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells” that recently appeared in Nature Reviews Microbiology (volume 12 March 2014 pp. 159-167). In this article, Dr. Dartois describes new methods to quantify and image drug distribution in infected lung tissue and in mycobacterial cells, and she explores how this technology could be used to design optimized multidrug regimens. To download or request a PDF copy of the article, please visit the web site of Nature Nature Reviews Microbiology at www.nature.com

Dr. Dartois has demonstrated that the distribution of antibiotics in the lesions of TB infected individuals is not uniform. In another review, in press, entitled “Heterogeneity in tuberculosis pathology, microenvironments and therapeutic reponses”, she and her co-authors present evidence that the prevailing view which claims that all TB induced lesions in an individual react similarly to the systemic immune response and to antibiotic therapies is not valid. In fact, host pathogen interactions within lesions are a dynamic process and result in a spectrum of TB lesions in each infected individual. This new paradigm will be helpful to TB researchers who are studying the pathogenesis of tuberculosis and its treatment. To download a PDF copy of the article, please follow this link.

Dr. Véronique Dartois is Associate Professor at PHRI and the department of Medicine at the New Jersey Medical School, Rutgers, the State University of New Jersey

Dr. Dartois features in the Gifts & Grants section of the March 18 edition of Rutgers Faculty & Staff Bulletin at bulletin.rutgers.edu/

Faculty Positions Infectious Diseases Research

The Public Health Research Institute (PHRI) of New Jersey Medical School - Rutgers University located in Newark, New Jersey, is recruiting a new faculty member at the middle or senior levels to join a growing group of 23 laboratories. PHRI is a leading infectious diseases research center that emphasizes basic and translational sciences. Candidates must have training and experience of the highest quality, and a NIH funded research program addressing critical questions in cell biology, immunology and molecular biology that offer novel insights into pathogenicity, as well as innovative approaches for new vaccines, therapeutics and diagnostics. The PHRI Center is housed in a state of the art research facility that has extensive core services, including nationally designated BL3 laboratory and animal facilities, X-ray facility for structural studies and applied genomics center. The PHRI Center offers a robust and highly collegial research environment, generous start-up funds, and a comprehensive benefits package. Candidates should submit a curriculum vitae, a statement of research interests and accomplishments and a list of at least three references.

Any questions or applications should be sent to: Dr. Barry Kreiswirth, Public Health Research Institute, Rutgers, New Jersey Medical School, 225 Warren Street, Newark, NJ 07103. Telephone: (973) 854-3240. Fax: (973) 854-3101. Email: kreiswba@njms.rutgers.edu

Please note that effective July 1, 2013, as a result of the New Jersey Medical and Health Sciences Restructuring Act, several units from the former University of Medicine and Dentistry of New Jersey (UMDNJ) are now part of Rutgers Biomedical and Health Sciences (RBHS). For the purposes of payroll and benefits administration, the above position is a legacy UMDNJ position at Rutgers, and is eligible for benefits associated with legacy UMDNJ positions.

The PHRI is an Equal Opportunity Employer.

To download a PDF copy of this employment opportunity advertisement, which appeared in the February 7, 2014, issue of Science click here

  08.15.15   csmonitor.com: Octopus genome mapped: How weird are the eight-limbed critters?; nature.com: The octopus genome and the evolution of cephalopod neural and morphological novelties
  08.11.15   medicalxpress.com: Research advances potential for test and vaccine for genital and oral herpes
  08.10.15   medicalxpress.com: NYC mayor: Legionnaires' outbreak has claimed 12 lives
  08.08.15   medicalxpress.com: Record 108 contract Legionnaires disease in New York
  08.03.15   cdc.gov: CDC funding helps states address infectious disease threats
  08.03.15   cnn.com: Seven dead in Legionnaires' disease outbreak in New York
  07.29.15   consumerreports.org: America's antibiotic crisis: How your hospital can make you sick
  07.20.15   thelancet.com: Bringing fungal infections in from the cold
  06.13.15   reuters.com: WHO calls emergency meeting on 'large, complex' South Korea MERS outbreak and cdc.gov: MERS in Republic of Korea
  06.10.15   cbsnews.com: CDC looking for passenger carrying tenacious tuberculosis strain
  06.02.15   Wall Street Journal: Preserving the Blessings of Antibiotics

  07.08.15   Dr. Kelley Healey, postdoctoral fellow in the laboratory of Dr. David Perlin at the PHRI was awarded a 2015 Arnold O. Beckman Postdoctoral Fellow grant to support her research "Elucidating multi-drug resistance in fungal pathogens." For details on her award and research, please visit njms.rutgers.edu
  06.25.15   Dr. David Perlin, Director of PHRI, was interviewed for an article entitled "Can America stave off the superbug apocalypse?" To read the article, please visit www.theweek.com
  05.26.15   This month's Paper Highlights features a publication from Dr. Marcela Rodriquez laboratory. For details, please visit PHRI Paper Highlights
  05.26.15   PHRI investigator Dr. Chaoyang Xue received a new NIH grant entitled “Regulation of ubiquitin-proteasome in Cryptococcus pathogenesis.” Cryptococcus neoformans is the primary cause of fungal meningitis, killing as many as 600,000 people a year. Presently, there is an incomplete understanding of disease mechanisms and host-pathogen interactions in this organism. Dr. Xue’s work has demonstrated that cryptococcal pathogenicity requires a key component of the ubiquitin-proteasome system, providing the first link between regulated protein turnover and fungal virulence. In this project, Dr. Xue will further investigate this link by focusing on the mechanisms by which fungal protein turnover regulates host-pathogen interactions. Understanding how the ubiquitin-proteasome pathway controls fungal disease development could facilitate efforts to design new therapeutic agents that interact with this pathway and its downstream effectors, and may have potential for a novel vaccine strategy.
  05.01.15   In the Spring 2015 issue of Rutgers’ Pulse Magazine, an article appeared discussing the work of PHRI faculty members David Perlin and Salvatore Marras.

Pulse magazine can be viewed at www.njms.rutgers.edu.



     Copyright © 2015 All rights reserved.   PHRI at ICPH 225 Warren St. Newark, NJ 07103-3535 TEL 973 854 3100, FAX 973 854 3101